Spanish multicenter study of the epidemiology and mechanisms of amoxicillin-clavulanate resistance in Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3576-3581

  Ortega, Adriana ^a   Oteo, Jesús ^a   Aranzamendi Zaldumbide, Maitane ^b   Bartolomé, Rosa M ^c   Bou, Germán ^d   Cercenado, Emilia ^e   Conejo, M Carmen ^f   González López, Juan José ^c   Marín, Mercedes ^e   Martínez Martínez, Luis ^b,g   Merino, María ^d   Navarro, Ferran ^c,h   Oliver, Antonio ⁱ   Pascual, Álvaro ^f,j   Rivera, Alba ^h   Rodríguez Baño, Jesús ^f,j   Weber, Irene ⁱ   Aracil, Belén ^a   Campos, José ^a,k  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f UNIVERSITY OF SEVILLE   (Spain)

^g UNIVERSITY OF CANTABRIA   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k CSIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE TEM 1; BETA LACTAMASE TEM 185; BETA LACTAMASE TEM 30; BETA LACTAMASE TEM 32; BETA LACTAMASE TEM 33; BETA LACTAMASE TEM 34; BETA LACTAMASE TEM 35; BETA LACTAMASE TEM 40; BETA LACTAMASE TEM 54; BETA LACTAMASE TEM 76; BETA LACTAMASE TEM 79; PENICILLINASE; PROTEIN OXA 1; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CLONAL VARIATION; COMMUNITY; ESCHERICHIA COLI; GENE SEQUENCE; GENETIC VARIABILITY; HOSPITAL; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS; SEQUENCE ANALYSIS; SEROTYPE; SPAIN;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MOLECULAR EPIDEMIOLOGY; PROSPECTIVE STUDIES; SPAIN;

EID: 84862575125     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06393-11     Document Type: Article

References (32)

1. TEM-containing transposons in commensal Escherichia coli. J. Antimicrob. Chemother. 66:745-751.
2. Biendo M, et al. 2005. Molecular characterisation and mechanisms of resistance of multidrug-resistant human Salmonella enterica serovar Typhimurium isolated in Amiens (France). Int. J. Antimicrob. Agents 26:219-229.
3. Campos J, et al. 2007. Surveillance of outpatient antibiotic consumption in Spain according to sales data and reimbursement data. J. Antimicrob. Chemother. 60:698-701.
4. Clermont O, Bonacorsi S, Bingen E. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66:4555-4558.
5. Clermont O, et al. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent phylogenetic subgroup. J. Antimicrob. Chemother. 61:1024-1028.
6. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 9th ed. Approved standard M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Crémet L, et al. 2010. Occurrence of ST23 complex phylogroup A Escherichia isolates producing extended-spectrum AmpC beta-lactamase in a French hospital. Antimicrob. Agents Chemother. 54:2216-2218.
9. Fluit AC, et al. 2000. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997-1998. Clin. Infect. Dis. 30:454-460.
10. García-Cobos S, et al. 2008. Antibiotic resistance in Haemophilus influenzae decreased, except for beta-lactamase-negative amoxicillin-resistant isolates, in parallel with community antibiotic consumption in Spain from 1997 to 2007. Antimicrob. Agents Chemother. 52:2760-2766.
11. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Project Group ESAC. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587.
12. Kaye KS, et al. 2004. Variety of β-lactamases produced by amoxicillin-clavulanate- resistant Escherichia coli isolate in the northeastern United States. Antimicrob. Agents Chemother. 48:1520-1525.
13. Lark RL, et al. 2001. Four-year prospective evaluation of community-acquired bacteremia: epidemiology, microbiology and patient outcome. Diagn. Microbiol. Infect. Dis. 41:15-22.
14. TEM genes and their relationship to β-lactam resistance. Antimicrob. Agents Chemother. 46:4035-4037.
15. Lázaro BE, Madurga SM, de Abajo FJ. 2002. Evolución del consumo de antibióticos en España, 1985-2000. Med. Clin. (Barc.) 118:561-568.
16. TEM genes. Antimicrob. Agents Chemother. 44:2709-2714.
17. Martin O, et al. 2010. Population analysis and epidemiological features of inhibitor-resistant-TEM-β-lactamase-producing Escherichia coli isolates from both community and hospital settings in Madrid, Spain. J. Clin. Microbiol. 48:2368-2372.
18. Miró E, et al. 1998. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with coamoxiclav due to SHV-1 hyperproduction. J. Antimicrob. Chemother. 42:535-538.
19. Miró E, et al. 2002. Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant β-lactamases at a university hospital in Barcelona, Spain, over a 3-year period. Antimicrob. Agents Chemother. 46:3991-3994.
20. Oteo J, et al. 2008. Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain. Emerg. Infect. Dis. 14:1259-1262.
21. Oteo J, et al. 2010. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn. Microbiol. Infect. Dis. 67:270-276.
22. Oteo J, et al. 2005. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg. Infect. Dis. 11:546-553.
23. Oteo J, et al. 2006. Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J. Clin. Microbiol. 44:2359-2366.
24. Pérez-Moreno MO, et al. 2004. Mechanisms of reduced susceptibility to amoxycillin-clavulanic acid in Escherichia coli strains from the region of Tortosa (Catalonia, Spain). Clin. Microbiol. Infect. 10:234-241.
25. Pérez-Pérez FJ, Hanson ND. 2002. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol. 40:2153-2162.
26. Robin F, et al. 2007. Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient. Antimicrob. Agents Chemother. 51:1304-1309.
27. Sirot D, et al. 1994. Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to β-lactamase inhibitors. J. Antimicrob. Chemother. 33:1117-1126.
28. Stapleton P, et al. 1995. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob. Agents Chemother. 39:2478-2483.
29. Sutcliffe JG. 1978. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc. Natl. Acad. Sci. U. S. A. 75:3737-3741.
30. TEM promoter variant. J. Antimicrob. Chemother. 58:183-185.
31. Waltner-Toews RI, et al. 2011. Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended-spectrum-beta- lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction. Antimicrob. Agents Chemother. 55:495-501.
32. Zhou XY, Bordon F, Sirot D, Kitzis MD, Gutmann L. 1994. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 β-lactamase conferring resistance to β-lactamase inhibitors. Antimicrob. Agents Chemother. 38:1085-1089.